Management of Fluoroquinolone-Resistant Urinary Tract Infections

Immediate Management Algorithm

The European Association of Urology recommends switching to an extended-spectrum cephalosporin, such as ceftriaxone 1-2g daily, or an aminoglycoside, such as gentamicin 5mg/kg daily, when urine culture demonstrates resistance to both levofloxacin and ciprofloxacin 1, 2
For uncomplicated pyelonephritis requiring hospitalization, the European Urology guidelines suggest ceftriaxone 1-2g IV once daily as the preferred initial choice, given its broad coverage and favorable dosing 1, 2
Cefepime 1-2g IV twice daily is an alternative extended-spectrum cephalosporin for uncomplicated pyelonephritis requiring hospitalization 1, 2
Gentamicin 5mg/kg IV once daily is an effective option, but requires monitoring for nephrotoxicity and ototoxicity 1, 2
Amikacin 15mg/kg IV once daily is an alternative aminoglycoside for uncomplicated pyelonephritis requiring hospitalization 1, 2
Piperacillin/tazobactam 2.5-4.5g IV three times daily is a broad-spectrum beta-lactam/beta-lactamase inhibitor combination for uncomplicated pyelonephritis requiring hospitalization 1, 2

Trimethoprim-sulfamethoxazole 160/800mg twice daily for 14 days is an option for oral step-down therapy, but only if the organism is susceptible 3, 2
Cefpodoxime 200mg twice daily for 10 days is an oral cephalosporin option for step-down therapy 2
Ceftibuten 400mg once daily for 10 days is an alternative oral cephalosporin for step-down therapy 2

The European Association of Urology guidelines state that fluoroquinolone resistance >10% mandates alternative empirical therapy, and documented resistance on culture absolutely requires switching 1, 2
Fluoroquinolone resistance suggests possible ESBL-producing organism, recent fluoroquinolone exposure, healthcare-associated infection risk, and need to classify as complicated UTI 2

Carbapenems, such as imipenem/cilastatin 0.5g three times daily or meropenem 1g three times daily, should be considered for ESBL-producing organisms 1, 2
Novel agents, such as ceftolozane/tazobactam 1.5g three times daily, ceftazidime/avibactam 2.5g three times daily, or cefiderocol 2g three times daily, are options for multidrug-resistant organisms 1, 2

Beta-lactams are less effective than fluoroquinolones for susceptible organisms, but remain appropriate when fluoroquinolones are not an option, as long as documented susceptibility and adequate dosing are ensured 3, 1, 2

Avoid nitrofurantoin, fosfomycin, and pivmecillinam for pyelonephritis due to insufficient data supporting their efficacy for upper tract infections 1
Do not use oral beta-lactams as monotherapy without an initial IV loading dose of ceftriaxone or aminoglycoside 3, 2
Aminoglycosides should not be used as monotherapy for pyelonephritis without supporting data, and require monitoring for serious irreversible toxicities 3

Extended-spectrum cephalosporins or aminoglycosides should be continued IV until clinical improvement, then transitioned to oral agent based on susceptibilities for a total of 10-14 days 3, 2
Trimethoprim-sulfamethoxazole should be given for 14 days total if the organism is susceptible 3, 2
Oral cephalosporins should be given for 10 days 2